When was Inscripta founded?

Inscripta was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Inscripta located?

Inscripta is headquartered in Denver, United States.

How many employees does Inscripta have?

As of Mar 20, 2025, the latest employee count at Inscripta is 73.

Is Inscripta a funded company?

Inscripta is a funded company, having raised a total of $502M across 12 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 04, 2016.

When was the latest funding round of Inscripta?

Inscripta's latest funding was a $***** Series E round on Dec 12, 2022, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.25B in funding in 2026 to date.

Where does Inscripta rank among its competitors?

Inscripta ranks 89th amongst 680 active competitors, of which 160 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Inscripta?

Inscripta's top competitors include Ginkgo Bioworks, Syngenta and Spark Therapeutics. Among them, Antheia secured the most recent funding round in January, 2026.

Inscripta - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of gene editing technology for research. The product portfolio of the company includes developing a family of CRISPR enzymes (called MADzymes), bespoke nucleases for researchers and commercial partners, and a full suite of gene editing tools (software, instruments, and reagents) to increase the speed and efficiency of precision gene editing.

Website: www.inscripta.com/
Social
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

Denver, United States

Stage

Series E

Total Funding

$502M in 12 rounds

Latest Funding Round

Series E, Dec 12, 2022, $*****

Investors

Paladin Capital & 20 more

Ranked

89^th among 680 active competitors

Employee Count

73 as on Mar 20, 2025

Investment & Acquisitions

Infinome Biosciences & 2 more

Similar Companies

Ginkgo Bioworks & 375 more

View Inscripta's full profile

Inscripta is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Inscripta, Inc CIN: 47-4648713 , United States, Active	May 10, 2016	-	-	-

Inscripta has raised a total funding of $502M over 12 rounds. Its first funding round was on Feb 04, 2016. Inscripta has 21 institutional investors.

Here is the list of recent funding rounds of Inscripta:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 12, 2022	5033058	Series E	1278958	1887449	4250590	8403899
Nov 24, 2021	2793984	Series E	2534775	9511122	3729905	4678033
Mar 30, 2021	4310184	Series E	9517952	6950837	Fidelity Investments	Durable Capital Partners & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Inscripta's funding rounds and investors

The founders of Inscripta are Tanya Lipscomb and Andrew Garst.

Here are the details of Inscripta's key team members:

Tanya Lipscomb: Former Co-Founder of Inscripta. They serve on the board of 1 company.
Contact Info: 1 email address
Andrew Garst: Co-Founder of Inscripta.
Contact Info: 1 email address

Inscripta's Board of Directors

Inscripta's board has 19 active members. John Stuelpnagel, Bryan Roberts, Tanya Lipscomb, Eric Moessinger, Roger Wyse, Sri Kosaraju, Dianna L. DeVore, Kevin D. Ness, Sri Kosaraju, Andrew D. Garst, Michael Graige, Ron Mcgrath, Jason T. Gammack, Ryan T. Gill, Justin Ferber, Kristala L. Jones Prather, Jason Gammack, John R. Stuelpnagel and Dianna Devore are independent board members.

Here is the list of Inscripta's board of directors:

Name	Type	Representing	Status	Duration
John Stuelpnagel	Independent board member	-	Current	9y 6m
fqgncxn	Independent board member	-	Current	4y 9m
qp{pq{m	Independent board member	-	Current	7y 6m
xjsgrqr	Independent board member	-	Current	2y 8m
vpvvuie	Independent board member	-	Current	7y 3m
xuziav{	Independent board member	-	Current	2y 4m
zgczvkx	Independent board member	-	Current	9y 3m
hezranc	Independent board member	-	Current	6y 6m
jyvspvi	Independent board member	-	Current	9y 2m
ogsuavp	Independent board member	-	Current	6y 4m
cvedkll	Independent board member	-	Current	5y 8m
duoyvls	Independent board member	-	Current	2y 3m
zvviuol	Independent board member	-	Current	7y 1m
xfuffuy	Independent board member	-	Current	8y 9m
qeuwsxv	Independent board member	-	Current	8y 7m
schx{wk	Independent board member	-	Current	9y 8m
ovffepj	Independent board member	-	Current	6y 8m
f{id{tz	Independent board member	-	Current	7y 9m
zikdgkf	Independent board member	-	Current	6y 9m

View details of Inscripta's Founder profiles and Board Members

Inscripta's employee count trend

Inscripta has 73 employees as of Mar 25. Here is Inscripta's employee count trend over the years:

Uncover Inscripta's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Inscripta include Ginkgo Bioworks, Syngenta and Spark Therapeutics. Here is the list of Top 10 competitors of Inscripta, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ginkgo Bioworks 2008, Boston (United States), Public	Autonomous labs for biotechnology, empowering scientists to design the living world	$796M	Viking Global Investors, T. Rowe Price & 53 others	81/100
2nd	Syngenta 2000, Basel (Switzerland), Acquired	Developer of technologies and sustainable farming practices for farmers	-	Analah Ventures, Europa	75/100
3rd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
4th	Twist Bioscience 2013, San Francisco (United States), Public	Developer of a semiconductor-based DNA synthesis platform	$321M	Foresite Capital, Fidelity Investments & 39 others	72/100
5th	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Cormorant-asset & 16 others	70/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Codexis 2002, Redwood City (United States), Public	Developer of high-performance enzymes for drug discovery	$111M	Vivo Capital, Malaysian Life Sciences Capital Fund ... & 12 others	68/100
8th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
9th	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	67/100
10th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
89th	Inscripta 2015, Denver (United States), Series E	Developer of gene editing technology for research	$502M	Foresite Capital, Fidelity Investments & 19 others	48/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Inscripta's competitors? Click here to see the top ones

Inscripta has acquired 3 companies including Infinome Biosciences, Sestina Bio and Solana Biosciences. Inscripta has not made any investments as of now.

Here is the list of its acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jan 18, 2023	Acquisition	Infinome Biosciences	2020	St. Louis (United States)
Jan 18, 2023	Acquisition	Sestina Bio	2020	Pleasanton (United States)
Sep 05, 2018	Acquisition	Solana Biosciences	2017	San Diego (United States)